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Clinical Aspects ofECL-Cell Abnormalities
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ECLcell hyperplasia results from hypergastrinemia, and in man this occurs due
to achlorhydria in atrophic gastritis (pernicious anemia [PA]) and gastrinoma
(Zollinger-Ellison syndrome [ZES]). Progression to neoplasia, i.e., ECL cell
carcinoids (usually small, multicentric and non-functional), occurs in some five
to 10percentofpatients withPAwherethey remaingastrin-dependentandrevers-
ibleby normalization ofserum gastrin by antrectomy. Even ifuntreated, the car-
cinoids are almost invariably benign and do not cause death. In ZES, ECL cell
hyperplasia is progressive due to hypergastrinemia. However, carcinoids develop
only in the MEN-I subtype but pose no additional threat ofmalignancy. A con-
servative approach is recommended for small multicentric carcinoids, and the
tumors do not need removal. By contrast, single, large, non-gastrin-dependent
carcinoids represent a different biological and clinical problem and are fre-
quently malignant
INTRODUCTION
In the last 15 years, both Enterochromaffinlike (ECL)b cell function and ECL cell
neoplasia have become the object ofmuch attention [1]. ECLfunction is now recognized as
being central to gastrin stimulation ofacid secretion viarelease ofhistamine and the control
and biology of the ECL cell has been extensively studied [1]. The clinical importance of
ECL cell abnormalities derive more from their neoplastic than their functional implica-
tions. Gastric fundic carcinoids were first associated withpernicious anemia over40 years
ago [2] and were considered to be a curiosity accounting for 0.3 percent of all gastric
tumors [3] and with a low rate ofmalignancy.
Neoplasia of the ECL cells was considered to be a minor and uncommon problem
until the observations that omeprazole, the most specific and potent inhibitor ofacid secre-
tion with resultant hypergastrinemia, was found to greatly increase the incidence ofgastric
carcinoids in susceptible rats [4-16]. Because ofthetherapeutic importance ofomeprazole and
the possibility ofa similar outcome in man [4], much effort was expended in understanding
the process of ECL cell neoplasia. The human counterpart of the achlorhydrialhypergas-
trinemia rat model, pernicious anemia (PA), was known to develop carcinoids [2], and
Rubin [7] identified endocrine cell hyperplasia associated with PA in 1969. Another
human hypergastrinemia condition, but with high acid secretion, the Zollinger-Ellison
syndrome (ZES), was felt to be at additional risk through the long-term use ofomeprazole.
Extensive observations over the last 12 to 15 years of patients treated with omepra-
zole, which may cause modest elevation of fasting serum gastrin [8], has laid to rest the
anxiety ofthe tumorigenic effect ofomeprazole directly or through acid inhibition [8, 9].
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ECL cell hyperplasia leading eventually to gastric carcinoids develops in rats with
prolonged hypergastrinemia of>1000 ng/l (>1000 pg/ml), which may be induced by long-
term administration of high-dose omeprazole [13-15], potent H2-antagonists [16-18],
antral exclusion [10], antral transplantation to the colon [11] orpartial resection ofthe gas-
tric fundus [12]. ECLcell hyperplasia is reversible with reversal ofhypergastrinemia [14],
and antrectomy, which prevents hypergastrinemia, also prevents ECL cell hyperplasia
during long-term administration of omeprazole [13, 14]. Therefore, gastric ECL cells
appear to be under the trophic control of gastrin in rats [12]. In mice, neither ECL cell
hyperplasia nor carcinoids were found with prolonged omeprazole treatment, perhaps
because of lower serum gastrin levels [13].
Two states of chronic hypergastrinemia of >1000 ng/l are found in humans, chronic
atrophic gastritis (CAG) and ZES. ECL cell hyperplasia is common both in CAG type A
or pernicious anemia [19-21] and in the ZES, in which it is less often micronodular [22-
24]. Gastric carcinoids, which are thought to evolve later [23], occur in up to five percent
ofpatients with CAG [19-21] but rarely in ZES syndrome [24-28] and are then associated
almost exclusively with multiple endocrine neoplasia [29]. In pernicious anemia, gastric
ECL carcinoids are usually multicentric and occur in the gastric body and fundus. Earlier
data suggested that a proportion of such tumors were potentially malignant [20, 22, 30],
and before the present level of understanding, some authors recommended total gastrec-
tomy [28, 31, 32]. This approach is now inappropriate, as the CAG-associated gastrin
dependent carcinoids rarely, ifever, cause death [33]
Unlike the functional aspect ofECLtumors inMastomys [1], where the oversecretion
of histamine by the ECL cell tumors has even more deleterious effects than the malig-
nancy, ECL cell proliferation and tumors (carcinoids) in man are overwhelmingly non-
functional. The problem then is to place the neoplasia in a clinical perspective.
ECL cell proliferation and progression to dysplasia and then neoplasia [1, 5] offers
the framework for classifying and understanding the clinical approach.
ECL cell hyperplasia occurs under several conditions ofhypergastrinemia:
1. CAG [5, 34], mostly associated with pernicious anemia (PA) (CAG
typeA) [30,34,35], butalso withnon-PAatrophicgastritis (typeB) [36].
2. Zollinger-Ellison syndrome, but almost exclusively in the MEN-I
subset [37- 39].
3. Patients treated long-term with omeprazole at doses that strongly
suppress acid secretion [9]
4. Patients with Helicobacter pylori infection, especially those with
long-term proton pump inhibitor acid suppression [40].
It is now felt that only patients in categories 1 and 2 (CAG, especially type A) and
(ZES with MEN-I) may progress to dysplasia and may develop carcinoids, whereas in
proton pump inhibitor therapy with or without H. pylori infection, ECL cell proliferation
does not progress beyond the stage ofhyperplasia or pseudohyperplasia [8] to dysplasia,
and the risk of carcinoid evolution is virtually nonexistent [9].
Gastric carcinoid tumors may also develop in the absence of hypergastrinemia and
these represent a more serious outcome [36, 41] and an entirely different therapeutic
approach. These tumors are to be differentiated from the neuroendocrine carcinomas.
Based on improved histological andimmunohistological criteria, several classifications
ofneuroendocrine tumors inthe stomach havebeenpresented [3,5,23,36,38], theirprecursor
lesions identified [3, 33, 36], andtheirsignificance and natural history related to theirback-
ground. These new perspectives have clarifiedand superseded theolderliterature [e.g.,42].
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CARCINOIDS ARISING IN CHRONIC ATROPHIC GASTRITIS
The majority of gastric carcinoids in man occur with CAG. Of the CAG cases with
carcinoid up to 90 percent of the A type [5, 8, 36], i.e., secondary to PA and associated
with hypergastrinemia [5, 34, 43] and precursor changes, hyperplasia and dysplasia, in the
fundic mucosa [41]. These tumors are well differentiated [3], small (<10 mm) and in 80
percent are multiple [3, 5]. In one study [3], two-thirds were mucosal, only one-third sub-
mucosal and none were invasive or metastatic, and in these and other series [5, 36, 41]
none died oftumors. Only three of91 cases collected by Solcia et al. [23] showed distant
metastases from CAG-related carcinoid. Associated lesions in CAG type Ainclude gastric
carcinoma (up to 10 percent [41]), and antral hyperplastic polyps, which may cause chronic
blood loss and may occur in as many as 20 percent ofpatients with carcinoids (personal
observation). On the basis of such observations, a conservative or semi-conservative
approach (see below) seemsjustified. Further support for aconservative stance comes from
the observations of spontaneous regression of tumors in small numbers of patients for
varying periods [44].
Based on the evidence that gastric carcinoids are the result ofahypergastrinemia and
that reversal of a hypergastrinemia by antrectomy, at least in rats, resulted in reversal of
carcinoids [14], such a surgical approach has been used in patients with CAG type A and
multicentric small carcinoids. We have followed three patients for seven to eight years
since antrectomy, which normalized gastrin. All showed rapid regression within six weeks
of the carcinoids [35] and, except for one transient recurrence ofa small carcinoid in two
of the patients at one year, both of which resolved spontaneously, no further tumors have
recurred, and all three now show only at most residual linear or nodular ECL cell hyper-
plasia. Similar results have been reported by Olbe et al. [45], Richards et al. [46], Solcia
[47], Caruso [48], Sjoblom [49] and Kern [32]. By contrast, Eckhauser et al. [30] reported
two cases, one ofwhom had a liver metastasis resected andthe other aregional lymph node;
in both, antrectomy normalized serum gastrin. The second patient had a gastric carcinoid
recurrence at four to six months, while the first was free of tumor. In another case [51]
with normalization ofserum gastrin by antrectomy, multiple carcinoids developed after23
months. However, thatpatient was secreting acid (MAO 6.8 mmol/hr) and thebackground
was not apparently not CAG-type A (pernicious anemia). The case is thus not clear.
Because of the low risk of tumor invasion and death from metastatic tumor [33, 41]
carcinoids may be approached on the basis ofbackground disease, tumor size and age of
the patient. Patients older than 65 or 70 should probably be watched expectantly ifinitial
evaluation shows (multiple) small tumors. In younger individuals, it is reasonable to recom-
mend antrectomy [5, 32, 35, 45, 47-49, 53] with expectation of long-term cure. Solitary
tumors greater than 1.5 cm should be excised.
Ifthe sequence of the gastrin-dependent development ofcarcinoids is hyperplasia -
dysplasia -* neoplasia (i.e., carcinoid) and neoplasia is defined as tumor progression
beyond the point at which the ECL proliferation becomes independent ofgastrin [1], then
one would expect none ofthe gastric carcinoids to regress after normalization ofthe gastrin.
Yet, 80 to 90 percent of cases reported have regressed permanently with normalization of
gastrin after antrectomy. Is the definition ofneoplasia then still valid, or are there stages of
carcinoid (e.g., defined by size, or cell characteristics) in which carcinoids are irreversible?
The cost/benefit of screening CAG type A by endoscopy for tumors, including carci-
noma, is discussed by Borch [19]. In patients with known carcinoids, follow-up endo-
scopy at one to two year intervals is advisable because ofpossible associated lesions such as
carcinoma [41], though no one has suggested that carcinoids are a marker for the develop-
ment of carcinoma in the same stomach.
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The role of gastrin in promoting hyperplasia of ECL cells clearly follows from the
physiological principle [45] that an agonist may cause both secretion and proliferation of
the target cell [43]. For most such agonists, these two actions are mediated by receptors
ofdiffering affinity, and this is also true ofthe effectofgastrin on ECLcells [52]. An addi-
tional mechanism that could be involved in the apparent hyperplasia of ECL cells in
hypergastrinemic CAG (i.e., PA) or in ZES-MEN-I is the prolongation oflife span ofthe
cells [5]. Such a prolongation may result from inhibition of apoptosis as previously sug-
gested [43]. Several candidate oncoproteins, e.g., myc [53] or BCL-2, are possible. BCL-
2 has been reported to be increased in ZES-MEN-I and increased more in CAG type A,
both conditions in which proliferation, atypia and neoplasia occur with intermediate and
high risk, respectively [54]. By contrast, in ZES (not MEN) BCL-2 is normal [54].
Withdrawal ofgastrin would then be expected to reverse the process, and evidence of
apoptosis should be sought in stomachs shortly after antrectomy. Experimentally this
could be tested in rats being treated with omeprazole [14].
Asmall proportion ofapparently well-differentiated carcinoids in CAG typeAstomachs
are larger (1.6-2 cm) and locally invasive [3, 5, 23]. It is not clearhow these wouldbehave
with antrectomy alone and may in fact represent the cases that did not regress [30, 55]
because they had progressed beyond gastrin dependence [1]. It is also unclear whether the
larger tumors represent a different subset or an unusual growth ofone ormore multicentric
tumors, which by my observations and those ofothers [23, 44] rarely change from year to
year. Because ofthe complexity ofmorphology ofendocrine cell tumors, it is not always
clear from published data that the exact cell type makeup of questionable tumors was
known, especially in the older literature. Some may in fact be neuroendocrine carcinomas
[5]. Such cases would obviously not be expected to benefit from antrectomy.
GASTRIC CARCINOIDS ASSOCLATED WITH ZES
With the hypothesis in hand that hypergastrinemia causes carcinoids, as appears clear
from the rat data [10-17] and from the case ofthe hypergastrinemic CAG with PA, it was
expected that the high gastrin levels in patients with ZES would cause carcinoids to develop.
In fact, ECL cell density in ZES is higher (i.e., ECL cell hyperplasia) than in controls and
duodenal ulcer, even in those DU patients with acid secretion in the ZE range [5, 9, 56-
58] and carcinoids do occurinpatients withZES [24-28]. However, itis now apparentthat
the carcinoids that do develop in ZES are almost exclusively seen in the MEN-I subtype
[2, 38, 59]. Cadiot [39] reported that five of 17 cases (30 percent) with MEN-I had carci-
noids, compared to none of31 with sporadic ZES. Solcia et al. [3] have collected 19 such
cases and describe the whole spectrum from simple hyperplasia to invasive tumor. Two of
6 cases reported by Rindi et al. [29] had lymph node spread, but no patient died of ECL
carcinoid in follow-up. These carcinoids do not require special intervention. Rarely carci-
noids may be found in MEN-I without the ZES component [23].
The probable basis for carcinoid development is not, therefore, hypergastrinemia
alone [3] butthepossible loss ofone or more tumor suppressing genes inMEN-I [60] with
the result of abnormal secretion by EC or ECL cells [3] of growth factors like gastrin or
B-fibroblast growth factor [1], which is abnormally elevated inpatients with MEN-I [61,62].
It has been suggested that H. pylori may contribute to ECLcell proliferation, perhaps
through a mechanism demonstrated in vitro showing stimulation ofECL cells and prolifera-
tion by H. pylori lipopolysaccharide [63], especially with hypergastrinemia or acid sup-
pression by lansoprazole [40]. We have re-examined this question in hypersecretors (BAO
> 15 meq/hr), both ZE (n = 31) and non-ZE (n = 12) and found that infection with H.
pylori had no effect on ECL cell counts before or after up to seven years oflansoprazole
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treatment to control acid secretion, and following a pre-treatment history that averaged
over 12 years, i.e., over a probable time-span of nearly 20 years [58]. Only one instance
ofcarcinoid was found, a ZE MEN-I patient (one offour such patients, 25 percent), who
was also H. pylori-negative.
SPORADIC ARGYROPHIL CARCINOIDS
These generally single tumors arise in the gastric body mucosa in patients with normal
serum gastrin and are, thus, different from the generally multicentric small benign carci-
noids seen in CAG and ZES-MEN-I [3, 36, 38, 41, 64]. These tumors represent 13 per-
cent of the gastric endocrine tumors reported by Solcia et al. [3, 36] and by Bordi et al.
[41]. They differ in other respects as well, being generally larger (median 2 cm diameter)
with a distinct tendency to invasion [3] and metastasis which is generally size-dependent
[64], features absent in gastric-dependent carcinoids [3]. Fewer than 10 percent of single
tumors <1 cm metastasized vs. 66 percent oftumors >3 cm [42]. Invasion into deepergas-
tric layers, vessels or lymphatics indicates aggressive behavior and poorprognosis. Those
with atypical morphology tend to be larger (>3 cm) and have poorer prognosis (5-year, 20
percent survival vs. 79 percent of the remainder [64]). The dominant cell type in these
tumors are also ECL cell type. The tumors are generally non-functional with some tumors
containing EC, X and G cells; occasionally an atypical carcinoid syndrome may be seen
when the tumor metastasizes to liver [3]. These isolated, non-gastrin-related carcinoids
thus have features in common with neuroendocrine carcinomas [36], unlike the gastrin-
dependent carcinoids should, thus, be treated aggressively by surgical removal [1, 41].
Local invasion or deep penetration may be estimated by endoscopic ultrasound, which
should be supplemented by CT scan and detailed immunohistochemical and electron
microscopic analysis ofthe tumor. Once metastasized, prognosis is very poor [1] and the
options more limited with removal if possible of metastases and symptomatic treatment
ofcarcinoid syndrome with octreotide as needed.
CONCLUSION
Much has been learned in recent years about the ECLcell and its role in acid secretion.
How the ECLcell and the six or more other types ofgastric mucosal endocrine cells affect
gastric physiology, growth orrepair remains obscure. Thus, the role ofpancreostatin, gas-
trocalcin, somatostatin and growth factors such as TGFa and gastrin-releasing peptide, as
well as currently unknown functions ofgastrin and histamine are still conjectural [1].
The causes and course of hyperplasia, dysplasia and progression to neoplasia are
incompletely understood [1], particularly in man. The progression from hyperplasia to
dysplasia to neoplasia appears to occur only or nearly only in limited cases of hypergas-
trinemia-CAG, especially type A and ZES-MEN-I. H. pylori appears irrelevant in this
context, as does treatment with proton pump inhibitor.
Theprogression to neoplasia is more clearly defined in Mastomys as defined by gastrin
independence [1, 65]. It is unclear whether the same occurs in man. In the one model,
CAG typeA, reversal ofhypergastrinemia results in regression ofcarcinoids in nearly all
cases. Further evaluation of the biology of the tumors that fail to respond appears war-
ranted. The relatively low level ofmalignancy and absence offunction allows one to adopt
a conservative approach to multicentric small carcinoids that are the rule. The solitary
non-gastrin-dependent large carcinoid, however, does not in the first place fit the gastrin
model and is clearly a different biological and clinical problem.
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